Chimagen Biosciences
恩沐生物（Chimagen Biosciences；集團識別）
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-09-15 | GSK plc | Trispecific T-cell engager for multiple myeloma | Not disclosed | Not disclosed | ≤ USD 750,000,000 | Preclinical; Phase 1 planned for 2027 |